Research
Hormonal
GLP-1 receptor agonists, particularly semaglutide, may worsen diabetic retinopathy (DR) upon initiation.
Clinicians should monitor diabetic retinopathy closely when initiating GLP-1 receptor agonists.
StrongQualifiesmedium confidence
some studies indicate a worsening of DR with the initiation of GLP-1 agonists, especially semaglutide.
Why this rating
Based on multiple large randomized controlled trials.
Source
Glucagon-like Peptide-1 Receptor Agonists in the Management of Diabetic Retinopathy
Anindya Samanta et al. · International Ophthalmology Clinics · 2024
DOI 10.1097/iio.0000000000000541
reviewCited 6×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →